{"url_path":"/sec/uncy/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER INFORMATION**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-054708-index.html","accession_number":"0001213900-26-054708","cik":"0001766140","ticker":"UNCY","issuer_name":"Unicycive Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-054708-index.html","primary_entity_key":"0001766140","primary_entity_name":"Unicycive Therapeutics, Inc."},"word_count":72,"has_tables":true,"body_markdown":"**ITEM 5. OTHER INFORMATION**\n\n \n\nMaterial changes to\nthe procedures by which security holders may recommend nominees to the board of directors.\n\n \n\nNone.\n\n \n\n*Director and Officer Trading Arrangements*\n\n \n\nDuring our quarter ended March 31, 2026, none\nof our directors or executive officers adopted, modified or terminated a “Rule 10b5-1 trading arrangement”\nor a “non-Rule 10b5-1 trading arrangement” as such terms are defined under Item 408 of Regulation S-K of the Exchange Act.\n\n \n\n41"}